Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS: Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo. The primary end point was overall survival. Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life. RESULTS: The median duration of survival was 20.3 months in the group given IFL plus bevacizumab, as compared with 15.6 months in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001). The median duration of progression-free survival was 10.6 months in the group given IFL plus bevacizumab, as compared with 6.2 months in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 percent and 34.8 percent (P=0.004). The median duration of the response was 10.4 months in the group given IFL plus bevacizumab, as compared with 7.1 months in the group given IFL plus placebo (hazard ratio for progression, 0.62; P=0.001). Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs. 2.3 percent) but was easily managed. CONCLUSIONS: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Necrosis promotes the expression of VEGFa, as dying tumor cells release signals that stimulate the growth of new blood vessels33,53.”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“Subsequently, as several phase III trials had demonstrated that FOLFOX and XELOX are comparable in the context of metastatic colorectal cancer33–35”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [33]
In the citing paper
“It has been reported that increased SFK expression occurs in approximately 80% of CRC specimens when compared to the normal adjacent colonic epithelium (Hurwitz et al., 2004).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hurwitz et al., 2004
In the citing paper
“The median overall survival in the IFL and bevacizumab arm was 20.3 months versus 15.6 months in the IFL alone arm.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [46]
In the citing paper
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [121]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Self-citationKim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Self-citationIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationYang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Self-citation
Research works printed but not linked: 4
- Presta LG, 1997, Cancer Res, 57, 4593
- Nissen NN, 1998, Am J Pathol, 152, 1445
- Hurwitz H, 2002, Prog Proc Am Soc Clin Oncol, 21, 82
- Benson AB, 2003, Prog Proc Am Soc Clin Oncol, 22, 243
Cited by
Items 1,001–1,082 of 1,082
Young, A., Chapman, O., Connor, C., Poole, C., Rose, P., & Kakkar, A. K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.106 · Cited by 150
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
Dunn, E. F., Iida, M., Myers, R. A., Campbell, D. A., Hintz, K. A., Armstrong, E. A., Li, C., & Wheeler, D. L. (2011) · Oncogene · doi:10.1038/onc.2010.430 · Cited by 133
“Furthermore, it has been reported that increased SFK expression occurs in B80% of CRC specimens when compared with the normal adjacent colonic epithelium (Hurwitz et al., 2004).”
BackgroundBevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
Morris, V., Overman, M. J., Jiang, Z.-Q., Garrett, C., Agarwal, S., Eng, C., Kee, B., Fogelman, D., Dasari, A., Wolff, R., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.06.001 · Cited by 132
Colorectal cancer and immunity: What we know and perspectives
Pernot, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3738 · Cited by 131
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“Another trial evaluated the use of bevacizumab as adjuvant therapy after surgery [51].”
BackgroundAngiogenesis Inhibitors and Hypertension: An Emerging Issue
Sica, D. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5740 · Cited by 127
The role of the PI3K pathway in colorectal cancer
Papadatos-Pastos, D., Rabbie, R., Ross, P., & Sarker, D. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.006 · Cited by 126
Borner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn058 · Cited by 124
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2887 · Cited by 121
“In addition to chemotherapy, patients with RAS wildtype tumors may receive either anti–epidermal growth factor receptor (EGFR) or anti–vascular endothelial growth factor (VEGF) –directed agents.(1-6) Both strategies were compared in two randomized phase III trials: FIRE-3 (FOLFIRI as chemotherapy backbone) and CALGB 8…”
BackgroundBiomaterial‐Based Implantable Devices for Cancer Therapy
Chew, S. A., & Danti, S. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201600766 · Cited by 121
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
Memarzadeh, F., Varma, R., Lin, L.-T., Parikh, J. G., Dustin, L., Alcaraz, A., & Eliott, D. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2441 · Cited by 117
“Bevacizumab is an antibody against VEGF that has been approved by the US Food and Drug Administration for the treatment of colorectal cancer.(11) Several case reports have described the successful, off-label intravitreal use of bevacizumab for treatment of neovascularization associated with proliferative diabetic reti…”
Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
When are ‘positive’ clinical trials in oncology truly positive?
Ocana, A., & Tannock, I. F. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq463 · Cited by 110
VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs
Cao, Y. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.114 · Cited by 109
Zheng, Y., Zhou, R., Cai, J., Yang, N., Wen, Z., Zhang, Z., Sun, H., Huang, G., Guan, Y., Huang, N., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0025 · Cited by 105
Kubicka, S., Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt231 · Cited by 104
Kyula, J. N., Van Schaeybroeck, S., Doherty, J., Fenning, C. S., Longley, D. B., & Johnston, P. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0014 · Cited by 99
Rocca, Y. S., Roberti, M. P., Juliá, E. P., Pampena, M. B., Bruno, L., Rivero, S., Huertas, E., Sánchez Loria, F., Pairola, A., Caignard, A., et al. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00413 · Cited by 97
Elimination of Neoangiogenesis for Plaque Stabilization
Kolodgie, F. D., Narula, J., Yuan, C., Burke, A. P., Finn, A. V., & Virmani, R. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.083 · Cited by 96
Yoon, J., Koo, K.-H., & Choi, K.-Y. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3058 · Cited by 92
Aparicio, T., Ghiringhelli, F., Boige, V., Le Malicot, K., Taieb, J., Bouché, O., Phelip, J.-M., François, E., Borel, C., Faroux, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2931 · Cited by 91
Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2892 · Cited by 88
Alternative clinical end points in rectal cancer—are we getting closer?
Glynne-Jones, R., Mawdsley, S., Pearce, T., & Buyse, M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl173 · Cited by 88
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Nisancioglu, M. H., Betsholtz, C., & Genové, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4245 · Cited by 87
Bélanger, A.-S., Tojcic, J., Harvey, M., & Guillemette, C. (2010) · BMC Molecular Biology · doi:10.1186/1471-2199-11-9 · Cited by 86
Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature
Hooglugt, A., van der Stoel, M. M., Boon, R. A., & Huveneers, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.612802 · Cited by 82
Fazzone, W., Wilson, P. M., LaBonte, M. J., Lenz, H., & Ladner, R. D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24403 · Cited by 80
Calvani, M., Trisciuoglio, D., Bergamaschi, C., Shoemaker, R. H., & Melillo, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5564 · Cited by 80
Peeters, M., Strickland, A. H., Lichinitser, M., Suresh, A. V. S., Manikhas, G., Shapiro, J., Rogowski, W., Huang, X., Wu, B., Warner, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.594 · Cited by 79
“These AEs are of interest because they have been reported in studies of patients with mCRC receiving 5-FU–based chemotherapy plus VEGF pathway inhibitors (Hurwitz et al, 2004; Giantonio et al, 2007; Saltz et al, 2008; Van Cutsem et al, 2011).”
BackgroundRecent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“The anti-VEGF antibody bevacizumab (BEV) is used in combination with chemotherapy (FOLFOX or FOLFIRI) for the treatment of mCRC with activating mutations in the RAS/RAF/MAPK pathway [121].”
BackgroundReduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Yan, P., Klingbiel, D., Saridaki, Z., Ceppa, P., Curto, M., McKee, T. A., Roth, A., Tejpar, S., Delorenzi, M., Bosman, F. T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0939 · Cited by 78
Therapy for Metastatic Colorectal Cancer
Goldberg, R. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-9-981 · Cited by 78
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro
O'Neill, E. C., Qin, Q., Van Bergen, N. J., Connell, P. P., Vasudevan, S., Coote, M. A., Trounce, I. A., Wong, T. T. L., & Crowston, J. G. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5669 · Cited by 73
“, South San Francisco, CA) is a full-length humanized monoclonal antibody directed against all isoforms of VEGF-A (VEGF-121, -145, -165, -183, -189, and -209) and is approved by the US Food and Drug Administration for the treatment of metastatic colorectal and metastatic breast cancer.(17,18) It binds and neutralizes…”
BackgroundMita, M., Kelly, K. R., Mita, A., Ricart, A. D., Romero, O., Tolcher, A., Hook, L., Okereke, C., Krivelevich, I., Rossignol, D. P., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0010 · Cited by 71
Richman, S. D., Chambers, P., Seymour, M. T., Daly, C., Grant, S., Hemmings, G., & Quirke, P. (2011) · Analytical Cellular Pathology · doi:10.1155/2011/393521 · Cited by 70
Hsu, M.-C., Pan, M.-R., & Hung, W.-C. (2019) · Cells · doi:10.3390/cells8030270 · Cited by 67
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
Pogue-Geile, K., Yothers, G., Taniyama, Y., Tanaka, N., Gavin, P., Colangelo, L., Blackmon, N., Lipchik, C., Kim, S. R., Sharif, S., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt140 · Cited by 61
Lorgis, V., Maura, G., Coppa, G., Hassani, K., Taillandier, L., Chauffert, B., Apetoh, L., Ladoire, S., & Ghiringhelli, F. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0748-5 · Cited by 60
Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications
Cao, Q., Tian, Y., Deng, Z., Yang, F., & Chen, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063358 · Cited by 60
Ding, C., Li, L., Yang, T., Fan, X., & Wu, G. (2016) · BMC Cancer · doi:10.1186/s12885-016-2834-8 · Cited by 56
Fiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4523-7 · Cited by 55
Yonucu, S., Yιlmaz, D., Phipps, C., Unlu, M. B., & Kohandel, M. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005724 · Cited by 46
Van Cutsem, E., Joulain, F., Hoff, P. M., Mitchell, E., Ruff, P., Lakomý, R., Prausová, J., Moiseyenko, V. M., van Hazel, G., Cunningham, D., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0402-9 · Cited by 49
Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3053 · Cited by 49
“In the past two decades, development and approval of mAbs that target angiogenesis (e.g., bevacizumab) and EGFR(cetuximabandpanitumumab)havebeenshowntoenhancethe ef fi cacy of chemotherapy (2, 3).”
Self-citationYu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
Host effects contributing to cancer therapy resistance.
Katz, O. B., & Shaked, Y. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.002 · Cited by 47
Park, J. A., Espinosa-Cotton, M., Guo, H.-F., Monette, S., & Cheung, N.-K. V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006680 · Cited by 46
Aflibercept in the Treatment of Metastatic Colorectal Cancer
Wang, T.-F., & Lockhart, A. C. (2012) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s7432 · Cited by 44
Guérin, E., Raffelsberger, W., Pencreach, E., Maier, A., Neuville, A., Schneider, A., Bachellier, P., Rohr, S., Petitprez, A., Poch, O., et al. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00120 · Cited by 44
Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
Hansen, T. F., Qvortrup, C., & Pfeiffer, P. (2021) · Cancers · doi:10.3390/cancers13051031 · Cited by 43
“In combination with IFL, a bolus regimen consisting of irinotecan and 5-fluorouracil (5FU), OS was extended by almost five months to 20 months [7].”
BackgroundDual-pH responsive micelle platform for co-delivery of axitinib and doxorubicin
Xu, X., Li, L., Zhou, Z., Sun, W., & Huang, Y. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.04.060 · Cited by 41
Clinical trials with anti‐angiogenic agents in hematological malignancies
Medinger, M., & Mross, K. (2010) · Journal of Angiogenesis Research · doi:10.1186/2040-2384-2-10 · Cited by 40
“Administration of bevacizumab, in combination with cytotoxic chemotherapy, conferred benefits to patients with metastatic colorectal cancer, non-squamous, non-small cell lung cancer and metastatic breast cancer [62-64].”
Targeted Therapies for Malignant Glioma: Progress and Potential
Mercer, R. W., Tyler, M. A., Ulasov, I. V., & Lesniak, M. S. (2009) · BioDrugs · doi:10.2165/00063030-200923010-00003 · Cited by 39
Catalá-López, F., Aleixandre-Benavent, R., Caulley, L., Hutton, B., Tabarés-Seisdedos, R., Moher, D., & Alonso-Arroyo, A. (2020) · Trials · doi:10.1186/s13063-019-3944-9 · Cited by 38
Chen, G., Li, W., Tzekov, R., Jiang, F., Mao, S., & Tong, Y. (2015) · Retina · doi:10.1097/iae.0000000000000301 · Cited by 36
Immunotherapies targeting tumor vasculature: challenges and opportunities
Dianat-Moghadam, H., Nedaeinia, R., Keshavarz, M., Azizi, M., Kazemi, M., & Salehi, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226360 · Cited by 36
Radiotherapy in combination with vascular-targeted therapies
Ciric, E., & Sersa, G. (2010) · Radiology and Oncology · doi:10.2478/v10019-010-0025-9 · Cited by 30
E, J., Xing, J., Gong, H., He, J., & Zhang, W. (2015) · Tumor Biology · doi:10.1007/s13277-014-2667-5 · Cited by 29
Strimpakos, A., Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Andreadou, A., Sgouros, J., et al. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.07.001 · Cited by 27
Receipt of Targeted Therapy and Survival Outcomes in Patients with Metastatic Colorectal Cancer
Koroukian, S. M., Booker, B. D., Vu, L., Schumacher, F. R., Rose, J., Cooper, G. S., Selfridge, J. E., & Markt, S. C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.50030 · Cited by 27
Salvatore, L., Bria, E., Sperduti, I., Hinke, A., Hegewisch-Becker, S., Aparicio, T., Le Malicot, K., Boige, V., Koeberle, D., Baertschi, D., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102202 · Cited by 26
Bennouna, J., Deslandres, M., Senellart, H., de Labareyre, C., Ruiz-Soto, R., Wixon, C., Botbyl, J., Suttle, A. B., & Delord, J.-P. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0142-1 · Cited by 26
Liu, B., Polack, M., Coudray, N., Claudio Quiros, A., Sakellaropoulos, T., Le, H., Karimkhan, A., Crobach, A. S. L. P., van Krieken, J. H. J. M., Yuan, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57541-y · Cited by 25
“Subsequently, as several phase III trials had demonstrated that FOLFOX and XELOX are comparable in the context of metastatic colorectal cancer 33 – 35 , we thuscombinedthebevacizumab+FOLFOX-4andbevacizumab+XELOX groups into a uni fi ed “ AVANT-experimental group ” and conducted a separate analysis…”
InfluentialZargar, P., Ghani, E., Mashayekhi, F., Ramezani, A., & Eftekhar, E. (2018) · Oncology Letters · doi:10.3892/ol.2018.8569 · Cited by 23
Scott, A. J., Basu Mallick, A., Dotan, E., Cohen, S. J., Gold, P. J., Hochster, H. S., Subramaniam, S., Barzi, A., Watts, G. S., Blatchford, P. J., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0169 · Cited by 18
“While antiangiogenics have demonstrated incremental improvement in survival benefit, resistance to angiogenic inhibition uniformly develops over months in patients with mCRC (12, 13).”
BackgroundAlterations of Microvascular Density in Bone Metastases of Adenocarcinomas
Lórincz, T., Tímár, J., & Szendrói, M. (2004) · Pathology & Oncology Research · doi:10.1007/bf03033743 · Cited by 17
Recent concepts of antiangiogenic therapy
Konno, H., Yamamoto, M., & Ohta, M. (2010) · Surgery Today · doi:10.1007/s00595-009-4150-2 · Cited by 16
Sun, D.-C., Shi, Y., Wang, Y.-R., Lv, Y., Yan, H., Mao, H., Wang, Z.-K., Wu, Z.-Y., Shi, W.-W., & Dai, G.-H. (2017) · Scientific Reports · doi:10.1038/s41598-017-14669-2 · Cited by 16
The history of angiogenesis inhibitors
Ribatti, D. (2007) · Leukemia · doi:10.1038/sj.leu.2404756 · Cited by 15
Babkoff, A., Zick, A., Hubert, A., Tarantino, P., & Grinshpun, A. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100032 · Cited by 14
Targeting Metastasis Through the Inhibition of Interleukin 6 and 8
Jayatilaka, H., & Phillip, J. M. (2019) · Breast Cancer Management · doi:10.2217/bmt-2019-0002 · Cited by 10
Menon, C., Bauer, T. W., Kelley, S. T., Raz, D. J., Bleier, J. I., Patel, K., Steele, K., Prabakaran, I., Shifrin, A., Buerk, D. G., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23499 · Cited by 11
Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives
Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E. (2024) · Cancers · doi:10.3390/cancers16050890 · Cited by 11
“Unfortunately, as detailed in the previous section, antiangiogenic treatment combined with chemotherapy causes only mild increases in survival, low response rates and moderate efficacy [19].”
BackgroundInfluentialUpdate on Anti-Angiogenesis Therapy in Colorectal Cancer
Ciombor, K. K., & Goldberg, R. M. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0292-3 · Cited by 11
Mizushima, T., Ide, Y., Murata, K., Ohashi, I., Yasumasa, K., Fukunaga, M., Takemoto, H., Tamagawa, H., Hasegawa, J., Hata, T., et al. (2013) · Oncology · doi:10.1159/000356018 · Cited by 8
Gao, J., Li, F., Liu, Z., Huang, M., Chen, H., Liao, G., Meng, J., Wang, Q., Zhao, H., Li, C., et al. (2021) · Medicine · doi:10.1097/md.0000000000027130 · Cited by 6
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6
“In this randomized study, 402 patients with metastatic CRC received irinotecan, 5-fluorouracil, leucovorin, and bevacizumab, while 411 patients received leucovorin alone and a placebo [18].”
Method
Metadata
- Authors
- Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F.
- Affiliations
- Duke University (US)
- Kaiser Permanente (US)
- Genentech (US)
- Sarah Cannon (US)
- Hematology and Oncology Associates of Northeastern Pennsylvania (US)
- Vanderbilt University (US)
- California Pacific Medical Center (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-06-03
- Volume
- 350
- Issue
- 23
- Pages
- 2335-2342
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2157769714
- Cited by
- 10,968
- References
- 14
- Citations by year
- 2026: 127 · 2025: 162 · 2024: 242 · 2023: 276 · 2022: 264 · 2021: 270 · 2020: 289 · 2019: 293 · 2018: 323 · 2017: 422 · 2016: 462 · 2015: 523 · 2014: 608 · 2013: 671 · 2012: 711
- FWCI
- 339.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k23ca085582-06)
- National Cancer Institute (K23 CA085582-04)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- bevacizumab, metastatic colorectal cancer, irinotecan, 5-fluorouracil, leucovorin, anti-VEGF monoclonal antibody, combination chemotherapy, overall survival, progression-free survival, hypertension, first-line therapy
- MeSH terms
- Bevacizumab, Irinotecan, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Quality of Life, Colorectal Neoplasms, Survival Analysis, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.